Clinical trial · Interventional
Neoadjuvant Chemoradiotherapy Followed By Surgery in Treating Patients With Limited-Stage Small Cell Lung Cancer
Phase I Study of Preoperative Chemo/Radiation (Concurrent Irinotecan/Cisplatin/RT) Followed by Surgery in Limited Stage Small Cell Lung Cancer (SCLC-LS)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy such as irinotecan and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Irinotecan and cisplatin may also make the tumor cells more sensitive to radiation therapy. Combining chemotherapy with radiation therapy before surgery may shrink the tumor so that it can be removed during surgery. PURPOSE: This phase I trial is studying the side effects of neoadjuvant radiation therapy given together with irinotecan and cisplatin followed by surgery in treating patients with limited-stage small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cisplatin | Drug | Cisplatin | ALIAS |
| conventional surgery | Procedure | — | UNRESOLVED |
| irinotecan hydrochloride | Drug | Irinotecan | ALIAS |
| neoadjuvant therapy | Procedure | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically or cytologically confirmed small cell lung cancer
* Limited stage disease (clinical stage I-IIIA) and meets the following criteria:
* Confined to 1 hemithorax
* No T4 disease based on malignant pleural effusion
* No N3 disease based on contralateral hilar or supraclavicular involvement
* Contralateral mediastinal (N3) nodes greater than 1.5 cm on CT scan must be biopsied to rule out pathologic involvement
* Measurable or evaluable disease
* Tumor must be able to be encompassed by limited radiotherapy field without significantly compromising pulmonary function
* No pleural effusion visible on chest x-ray (regardless of cytology)
* No prior complete tumor resection
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* Karnofsky 70-100%
Life expectancy
* Not specified
Hematopoietic
* Absolute granulocyte count at least 1,800/mm\^3
* Platelet count at least 100,000/mm\^3
Hepatic
* Bilirubin no greater than 1.5 mg/dL
* No known Gilbert's disease
Renal
* Creatinine no greater than 1.5 mg/dL
* Calcium less than 12.0 mg/dL
Cardiovascular
* No myocardial infarction within the past 6 months
* No congestive heart failure
* No uncontrolled arrhythmias
* No active unstable angina
Pulmonary
* Calculated postoperative FEV\_1 at least 800 cc
* No chronic obstructive pulmonary disease with FEV\_1 no greater than 1 L or uncontrolled bronchospasm in the unaffected lung
Other
* Not pregnant
* Negative pregnancy test
* Fertile patients must use effective contraception
* No other malignancy within the past 2 years except curatively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or any other noninvasive malignancy
* No history of seizures
* No history of uncontrolled psychiatric illness that would preclude giving informed consent or complying with study
* No active or uncontrolled infection
* No uncontrolled diabetes mellitus (random blood sugar at least 250 mg/dL)
* No other concurrent serious medical illness
* HIV negative
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* No prior irinotecan
* No prior topotecan
Endocrine therapy
* Not specified
Radiotherapy
* No prior radiotherapy to the chest or other areas containing 30% or more of marrow-bearing bone
Surgery
* See Disease Characteristics
Other
* No concurrent phenytoin, phenobarbital, or other antiepileptic prophylactic drugs
* No concurrent amifostineReferences
Publications (0)
Data not yet available